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Abstract
Background: Persistent residual immune activation and lipid dysmetabolism are characteristics of HIV positive
patients receiving an highly active antiretroviral therapy (HAART). Nuclear Receptors are transcription factors
involved in the regulation of immune and metabolic functions through the modulation of gene transcription.
The objective of the present study was to investigate for the relative abundance of members of the nuclear
receptor family in monocytic cells isolated from HIV positive patients treated or not treated with HAART.
Methods: Monocytes isolated from peripheral blood mononuclear cells (PBMC) were used for analysis of the
relative mRNA expressions of FXR, PXR, LXR, VDR, RARα, RXR, PPARα, PPARβ, PPARγ and GR by Real-Time
polymerase chain reaction (PCR). The expression of a selected subset of inflammatory and metabolic genes MCP-1,
ICAM-1, CD36 and ABCA1 was also measured.
Results: Monocytes isolated from HIV infected patients expressed an altered pattern of nuclear receptors
characterized by a profound reduction in the expressions of FXR, PXR, PPARα, GR, RARα and RXR. Of interest, the
deregulated expression of nuclear receptors was not restored under HAART and was linked to an altered expression
of genes which supports both an immune activation and altered lipid metabolism in monocytes.
Conclusions: Altered expression of genes mediating reciprocal regulation of lipid metabolism and immune
function in monocytes occurs in HIV. The present findings provide a mechanistic explanation for immune activation
and lipid dysmetabolism occurring in HIV infected patients and could lead to the identification of novel potential
therapeutic targets.
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Background
Despite improvements in antiretroviral therapy, to date,
the life expectancy of HIV infected patients remains
shorter than of the general population [1]. The reduction
in the AIDS defining clinical conditions is in part com-
pensated by the development of other co-morbidities,
often connected to short or long term metabolic tox-
icities, as well as to an immune activation status, which
can persist despite an effective therapeutic control
of HIV replication [2]. A systemic immune activation
drives to secretion of pro-inflammatory cytokines [3]
and inflammatory markers are strong and independent
predictors of mortality in HIV positive patients [4].
Lipid and cholesterol abnormalities are a common
finding in HIV infected persons. Both the HIV infection,
per se, and HAART have been linked to these metabolic
abnormalities and both represent a well identified risk
for the development of atherosclerotic complications [5].
Genes involved in lipid and cholesterol metabolisms in
humans are governed by a family of ligand activated
transcription factors [6].
Members of the nuclear receptor superfamily exert
their regulatory activity integrating regulatory effects
exerted by nutrients with intermediate metabolism by
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positively and negatively regulating the expression of
effector genes [6]. One peculiar characteristic of some
of these receptors is their ability to regulate the innate
and adaptive immune system. This regulation is, in
most cases, inhibitory in nature and results in a pro-
found counter-regulation of inflammatory signaling in
macrophages [7].
Nuclear receptors are important therapeutic targets
[8], and their patterns of expression in HIV infection are
unknown. We have recently demonstrated that the HIV
matrix protein p17 regulates the expression of proin-
flammatory and proatherogenic genes as well as nuclear
receptors FXR and PPARγ on monocytic cells in a
STAT-1 dependent manner [9]. Noteworthy, we pro-
vided evidence that exposure of monocytes to nuclear
receptors agonists abrogates the effect of p17 [9]. Sup-
porting the notion that nuclear receptors ligands could
be used in conjuction with conventional antiviral therap-
ies in the treatment of HIV infection it has been recently
demonstrated that the activation of nuclear receptor sig-
naling contributes to the repression of HIV-1 replication
in macrophages [10].
In the present study we analyzed the expression of
various nuclear receptors in monocytic cells of HIV
infected patients and correlated the expression of the
nuclear receptor PPARγ with that of CD-36, a mem-




We performed our pilot study on 24 subjects: 8
HAART- naïve HIV-infected patients, 8 HAART-treated
HIV-infected patients with a viral load < 50 copies/ml
from at least 6 months and 8 healthy controls. From
February to May 2011 8 never-treated HIV infected
patients meeting the clinical criteria of being ≥ 18 y old,
without other infections (acute or chronic) and/or his-
tories of dysmetabolic diseases (diabetes, dyslipidemias)
were enrolled. In addition, we enrolled 8 HIV positive
treated patients and 8 healthy controls, chosen among
staff members, matched for age and BMI and satisfying
the same exclusion criteria were enrolled. Authorization
for collecting and using blood samples from these per-
sons for ex vivo testing was granted by the ethical com-
mittee of Regione Umbria (Italy) on July 22, 2010
(authorization number CEAS 1654/20). An informed
written consent was obtained from each participant to
the study.
Isolation of CD14-derived peripheral blood mononuclear
cells (PBMC)
Peripheral whole blood samples (~ 30 ml) from patients
and healthy controls were withdrawn in vacutainer tubes
containing EDTA. PBMC were first isolated by density
gradient centrifugation using the Hystopaque reagent
(Pharmacia Biotech) and then positively selected using
CD14 magnetic beads and LS columns according to
the manufacturer’s instructions (Miltenyi Biotec). After
isolation monocytes were lysated with 1 ml TRIzol
reagent (Invitrogen).
RNA extraction and real-time PCR
Total RNA was isolated from CD14-monocytes using
the TRIzol reagent (Invitrogen) and reverse-transcribed
using random hexamer primers and Super Script-II
reverse transcriptase (Invitrogen). mRNA was quantified
by Real-Time quantitative PCR on iCycler apparatus
(Biorad) using specific primers: 18S: cggctaccacatccaa
ggaa and gctggaattaccgcggct; FXR: tacatgcgaagaaagtgt
caaga and actgtcttcattcacggtctgat; PPARα: acgattcgactca
agctggt and gttgtgtgacatcccgacag; PPARβ: gctgagaagag
gaagctggt and cgatgtcgtggatcacaaag; PPARγ: gctggcctcct
tgatgaata and ttgggctccataaagtcacc; LXR: cgcactacatctgc
cacagt and tcaggcggatctgttcttct; PXR: agctggaaccatgctg
actt and cacatacacggcagatttgg; VDR: gcccaccataagacct
acga and agaagctgggagtgtgtctg; GR: ggcaataccaggtttcagga
and tatgatctccaccccagagc; RARα: aggacaccatgaccttctcg
and gtctccgcatcatccatctc; RXR: cctttctcggtcatcagctc and
tgacggggttcataggtgag; MCP1: ccccagtcacctgctgttat and tcct
gaacccacttctgctt; ICAM1: agcttctcctgctctgcaac and cattg
gagtctgctgggaat; ABCA1: gcttgggaagatttatgacagg and aggg
gatgattgaaagcagtaa; CD36: tttctgtatgcaagtcctgat and attaag
ccaaagaataggcac. PCR amplifications and data analysis
were performed as described [11].
Biochemical analysis
Serum levels of total cholesterol, tryglicerides and High
density lipoproteins (HDL) were measured with enzym-
atic colorimetric methods (Cobas Integra 800, Roche,
Germany).
Quantification of HIV-1-RNA copy numbers in plasma
Plasma viral load was determined by quantitative reverse
PCR using Cobas Amplicor HIV-1 Monitor Test, version
1.5, Ultrasensitive (Roche Diagnostic, Indianapolis, Indiana,
USA). The limit of detection was 40 copies/ml plasma.
Quantification of the CD4+ lymphocytes subset
CD4+ cell count was carried out in peripheral whole
blood collected in EDTA by flow cytometry (CYTOMICS
FC 500 BECKMAN COULTER). The absolute count was
performed by Flow-count Fluorospheres on EPICS XL™
BECKMAN COULTER.
Statistical analysis
All values are expressed as the mean ± SEM of n obser-
vations per group. Comparisons of more than 2 groups
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were made with a one-way analysis of variance with
post-hoc Tukey’s tests. Correlation statistics between the
mRNA levels of CD36 and PPARγ were performed using
linear regression test. A P value of less than 0.05 was
considered as statistically significant.
Results
Patient characteristics
The most relevant characteristics of the patients enrolled
in this study are shown in Table 1. HAART-naïve HIV-
infected patients had a baseline CD4+ cell count of
396.6 ± 121 cells/ml and detectable HIV RNA (50% >
105 copies/ml). Under HAART therapy, the viral load
was always < 50 copies/ml and the CD4+ cell count was
significantly higher (851.1 ± 78). The analysis of the lipid
pattern revealed that HIV infected patients had a robust
reduction of total cholesterol and HDL levels, while
triglyceride levels were slightly higher, in comparison to
healthy donors. Under HAART, the levels of HDL and
total cholesterol were similar to those of healthy donors,
while the levels of triglycerides were not significantly
higher; despite this, an upward trend was observed. No
patients were under lipid-lowering medications. Overall,
the metabolic findings were consistent with previously
published data [5].
Analysis of nuclear receptor transcriptome
To evaluate the hypothesis that HIV infection may alter
the expression of nuclear receptors in monocytes, we
performed a semi-quantitative Real-Time PCR in cells
isolated from the subjects reported in Table 1. As shown
in Figure 1, we observed a strong down-regulation of
mRNA levels for FXR, PXR, PPARα, GR, RARα and
RXR both in HAART- naïve and in HAART-treated
patients. In contrast, up-regulations of VDR and PPARβ
mRNA levels were seen in HIV positive naïve patients
and were almost completely restored by HAART. Note-
worthy, LXR mRNA levels in HAART treated patients
were significantly induced compared to healthy donors
but not changed compared to HIV-infected patients.
Finally, the analysis of the PPARγ gene demonstrated
that the expression of this nuclear receptor was unmodi-
fied among the examined subjects. These observations
lead us to conclude that HIV infection is associated with
transcriptome alterations for many nuclear receptors
and that HAART is only partially effective in counter-
acting these.
Analysis of lipid and inflammatory markers
Since nuclear receptors exert their functions at the inter-
face between inflammation and lipid metabolism, we
evaluated the expression of genes involved in immune
regulation and lipid metabolism on monocytes isolated
from both HAART- naïve and HAART-treated HIV-
infected patients. As expected, a robust induction in the
expression of the pro-inflammatory chemokine MCP-1
was observed in monocytes of HIV-infected patients,
while the HAART mediated suppression of viral replica-
tion failed to normalize the mRNA level of this chemo-
kine (Figure 2A). CD36 is a scavenger receptor
mediating the uptake of oxidized low-density lipopro-
teins by monocytes. Here, we found that the expression
of CD36 was strongly down-regulated in both HIV
infected classes (Figure 2B). We also analyzed the rela-
tive mRNA expression of the cell adhesion molecule
ICAM-1 as well as of the protein transporter ABCA1
involved in cholesterol efflux from monocytes and found
that their expressions were unchanged in untreated HIV
infection as well as in HAART (Figure 2C and D).
Noteworthy, a significant correlation between the
mRNA levels of PPARγ and CD36 in HIV-infected naïve
patients as well as in patients receiving HAART
Table 1 Clinical characteristics of study participants
Subjects HEALTY (n=8) HIV POSITIVE (n=8) HAART (n=8) P
Sex (Male/Female) 4/4 6/2 6/2 -
Age (years) 45.2 ± 4.5 47.1 ± 4.6 44.8 ± 4.4 -
BMI 24.15 ± 1.29 23.35 ± 0.99 23.37 ± 0.65 -
White Blood Cells (cells/mm3) 6347 ± 685 4756 ± 1214 5740 ± 567 -
CD4+ (cells/ml) N/A 396.6 ± 121 851.1 ± 78 # # < 0.05
Cholesterol (mg/dl) 201.3 ± 7.7 133.5 ± 13.8 * 226.3 ± 13.4 # * < 0.05# < 0.05
HDL (mg/dl) 59.1 ± 5.9 28 ± 3.8 * 45.5 ± 5.9 # * < 0.05# < 0.05
Triglycerides (mg/dl) 86.1 ± 11.6 169.7 ± 50.1 181.6 ± 29 -
Viral Load (copies/ml) N/A 840000±552000 < 50 # * < 0.05# < 0.05
Therapy none none PI (n=5) and NNRTI (n=3) -
Blood pressure medications 2 3 2 -
*P<0.05 versus healthy donors, #P<0.05 versus HIV patients.
PI, protease inhibitor; NNRT, non-nucleoside reverse transcriptase inhibitor.
N/A, not applicable.
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(Figure 2F and 2G) but not in healthy subjects was
found (Figure 2E).
Discussion
This study reports that HIV infection is associated with
a profound dysregulation in the expression of genes en-
coding for members of the nuclear receptor super family
in circulating monocytes.
It is well known HIV infection is associated to a
chronic inflammatory condition and lipid abnormalities,
with the latter being a consequence or concurrent cause
of the inflammation state. Moreover, in treated patients,
in spite of an effective control of the viral replication as
well as in absence of pharmaco-induced dyslipidemias, a
residual persistent chronic inflammatory status, which























































































































































































Figure 1 Panels A-L. Nuclear receptor expression profile in CD14 monocytes isolated from healthy donors, HIV-infected and HAART-
treated HIV-infected patients. All values were normalized to relative expression of 18S mRNA and are expressed relatively to the expression of
each gene in healthy donors. Analysis was carried out in triplicate (n=8 subjects / group). *P<0.05 versus healthy donors. #P<0.05 versus HIV-
infected patients by ANOVA.
Renga et al. BMC Infectious Diseases 2012, 12:274 Page 4 of 7
http://www.biomedcentral.com/1471-2334/12/274
We now provide evidence that, during the course of
HIV infection, the expression of a large group of nuclear
receptors is dramatically reset in monocytes, that this
resetting is associated to a robust activation of circulat-
ing monocytes as demonstrated by 10–20 fold increase
in the monocytic expression of MCP-1- RNA, and that
HAART is not able to revert all the observed alterations.
Specifically, we have obtained evidence that HIV infec-
tion causes profound down-regulations for FXR, PXR,
PPARα, GR, RARα and RXRα. These down regulations
were also observed under effective HAART.
A common motif of these transcription factors is their
ability to activate counter-regulatory signals essential to
reduce inflammation [7,8]. Indeed, besides the canonical
anti-inflammatory activity of GR, FXR, PXR, PPARα,
RARα and RXRα attenuate the inflammatory responses
and their activations reduce immune dysfunction-driven
inflammation in a variety of experimental and clinical
settings [7,13]. Furthermore, data from a variety of gene
deficient mice strongly supports the general notion that
ablation of these receptors leads to the development of a
deregulated immunity and causes metabolic dysfunction
[7,13]. The present study is, therefore, a general model
to examine the effect of viral infection and to further
understand how HIV virus-induced inflammation and
immune-dysfunction progress in human disease.
The detected alterations in the nuclear receptor
expression are probably an indirect effect of viral repli-
cation, considering that only a very low number of circu-
lating monocytes is infected by HIV [14]. These changes
could be determined by either the chronic inflammatory
process, as seen in atherosclerosis, type 2 diabetes mel-
litus, intestinal chronic inflammation, including inflam-
mation driven gastrointestinal cancers, or the residual
immune activation and microbial translocation asso-



















































































































Figure 2 Panels A-D. Relative mRNA expression of MCP-1 (A), CD36 (B), ICAM-1 (C) and ABCA1 (D) in CD14 monocytes isolated from
healthy donors, HIV-infected and HAART-treated HIV-infected patients. All values were normalized to relative expression of 18S mRNA and
are expressed relatively to the expression of each gene in healthy donors. Analysis was carried out in triplicate (n=8 subjects / group). *P<0.05
versus healthy donors. #P<0.05 versus HIV-infected patients by ANOVA. Panels E-G. HIV positive patients but not healthy donors showed a
significant correlation between mRNA levels of CD36 and PPARγ. R, correlation coefficient; P, P value.
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also arise from the action of some HIV proteins that can
persist for a long time- in the body of virologically con-
trolled patients [21]. This latter hypothesis could explain
the persistent alterations observed in the group of
HAART-treated HIV-positive subjects. Indeed, recently
we have documented that the p17 HIV protein, which
can persist in lymph nodes germinal centers of patients
effectively treated [21], was able to down regulate PPARγ
and FXR expressions in both THP1 cells and in healthy
donors monocytes. Moreover, the serum from HIV+
patients containing high levels of anti p17 antibodies
was able to revert the down regulation of PPARγ and
FXR in their monocytes [9].
Thereby, this implicates that the reset expressions of
nuclear receptors, which are counter-inflammatory in
nature, are likely instrumental in the progression of viral
infection and the persistence of a chronic inflammatory
state. Noteworthy, it has been demonstrated that mem-
bers of nuclear receptor superfamily (i.e. GR, FXR, PXR,
RAR and RXR) regulate immune responses and a pro-
inflammatory state with the so called transrepression
pathway, able to inhibit NF-KB [22]. It remains unclear
whether the observed changes are causes or conse-
quences of the characteristic inflammatory profile in
HIV and whether NRs agonists can directly suppress
residual inflammation.
In addition to their role in regulating immune
responses, nuclear receptors regulate glucose and lipid
metabolism [6]. Indeed, FXR has been demonstrated to
regulate insulin secretion and sensitivity and FXR
ligands reduce lipid and glucose levels in murine models
of diabetes [23,24]. Similar beneficial effects on glucose
metabolism have been shown for PXR [25], as well as
for the fibrates (PPARα agonists) that are widely used
for treatment of dyslipidemic conditions [26]. In short,
abrogation of the expression of these genes might pro-
vide an explanation for immune dysfunction and dyslipi-
demia observed in HIV disease. Importantly, it has been
demonstrated that FXR activation results in a slight
reduction of HDL and in an induction of LDL [27], and
therefore its abrogation might also provide some explan-
ation for the hypo-cholesterolemia observed in HIV-
positive persons.
Another important observation we made was that two
nuclear receptors, VDR and PPARβ, appeared robustly
induced in monocytes of HIV-infected patients. In
addition, while the expressions of VDR and PPARβ
normalize, the expression of LXR becomes significantly
induced under HAART. This is an important obser-
vation, as a common side effect of LXR activation is
hyper-triglyceridemia [28], and therefore its induction
might provide a further explanation of the hyper-
triglyceridemia observed in HAART.
In this study we have also seen that monocyte expres-
sion of CD36, whose transcription is primarily regulated
by LXR, PPARγ and PXR, is markedly reduced by HIV
infection. This suggests that the transcription of this
gene is impaired in HIV monocytes. Noteworthy, we
found the mRNA levels of CD36 significantly correlated
with those of PPARγ in only HIV positive patients, thus
providing a prognostic/diagnostic value to our profiles.
Indeed, it has been previously demonstrated that HIV
infection results in substantial decreases in serum total
cholesterol, HDL and LDL levels and that subsequent
HAART initiation is associated with increases in total
cholesterol and LDL but little change in HDL [29].
Furthermore, patients with CD36 deficiency show
increased levels of chylomicron remnants and small
dense low-density lipoprotein (sdLDL) particles [30].
Thus, the reduction of CD36 gene expression we
reported in this study might contribute to the high levels
of total cholesterol in HIV positive persons taking
HAART. These results also highlight a potential thera-
peutic role for PPARγ agonists in treating HIV asso-
ciated dyslipidemia.
Conclusions
Here, we have demonstrated that the transcriptome of
several nuclear receptors is altered in monocytes during
HIV infection. Furthermore, HAART failed to reverse
this pattern with the exception for VDR and PPARβ.
However, given that chronic inflammation and dyslipide-
mias are common in HIV-suppressed patients and that
NRs seem to be directly or indirectly involved in this in-
fection, our preliminary results suggest further investiga-
tions in a HIV positive population longitudinally
followed from the starting of HAART and prompt to
study whether nuclear receptor agonists can exercise any
role in controlling residual inflammation and/or
dyslipidemia.
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